-
The Route Not Taken. EP13
The F-C acylation served as the critical ring-forming step, though it proved challenging, with modest yields reported by Biogen. ChemAIRS proposed optimized reaction conditions to improve this transformation (Figure 2). Additionally, the algorithm flagged potential side reactions that could compromise the cyclization efficiency (Figure 3), providing insights into reaction optimization.
넶12 2024-12-11 -
The Route Not Taken. EP12
Astrazeneca and Mitsubishi Tanabe Pharma Corporation have developed AZD5462, a small-molecule mimetic of relaxin H2 signaling at RXFP1, offering promise as a treatment for heart failure.
넶9 2024-12-11 -
The Route Not Taken. EP11
𝐒𝐲𝐧𝐭𝐡𝐞𝐭𝐢𝐜 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬 𝐟𝐨𝐫 𝐬𝐞𝐥𝐞𝐜𝐭𝐢𝐯𝐞 𝐂𝐁𝟐𝐑 𝐢𝐧𝐯𝐞𝐫𝐬𝐞 𝐚𝐠𝐨𝐧𝐢𝐬𝐭𝐬: 𝐂𝐡𝐞𝐦𝐀𝐈𝐑𝐒-𝐀𝐬𝐬𝐢𝐬𝐭𝐞𝐝 𝐑𝐨𝐮𝐭𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭
넶15 2024-11-06 -
The Route Not Taken. EP10
𝐏𝐫𝐞𝐝𝐢𝐜𝐭𝐢𝐨𝐧 𝐨𝐟 𝐂𝐨𝐧𝐯𝐞𝐫𝐠𝐞𝐧𝐭 𝐒𝐲𝐧𝐭𝐡𝐞𝐬𝐢𝐬 𝐟𝐨𝐫 𝐂𝐚𝐬𝐝𝐚𝐭𝐢𝐟𝐚𝐧 (𝐀𝐁𝟓𝟐𝟏) 𝐮𝐬𝐢𝐧𝐠 𝐂𝐡𝐞𝐦𝐀𝐈𝐑𝐒
넶12 2024-11-06 -
The Route Not Taken. EP9
Leveraging ChemAIRS to Investigate Synthetic Strategies for SGR-1505, a MALT1 inhibitor from Schrodinger
넶18 2024-09-25 -
The Route Not Taken. EP8
Leveraging ChemAIRS to Investigate Synthetic Strategies for Chiral Spirocyclic Isoxazolone, a Vital Building Block in a Boehringer Ingelheim Drug Development Program.
넶10 2024-09-25
